Tumor-derived transforming growth factor-β is critical for tumor progression and evasion from immune surveillance

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 13, 2014, Pages 5181-5186

  Li, Zheng ^a   Zhang, Li Juan ^b   Zhang, Hong Ru ^a   Tian, Gao Fei ^a   Tian, Jun ^a   Mao, Xiao Li ^c   Jia, Zheng Hu ^a   Meng, Zi Yu ^a   Zhao, Li Qing ^a   Yin, Zhi Nan ^a   Wu, Zhen Zhou ^a  

^a NANKAI UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

Author keywords

Immune surveillance; MDSC; ShRNA; Treg; Tumor derived TGF

Indexed keywords

GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; APOPTOSIS; BONE MARROW CELL; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; DISEASE COURSE; EXPERIMENTAL MELANOMA; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; MALE; MOUSE; NEOPLASM; PATHOLOGY; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; INTERFERON-GAMMA; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MONITORING, IMMUNOLOGIC; MYELOID CELLS; NEOPLASMS; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84905365499     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.13.5181     Document Type: Article

References (26)

1. Akhurst RJ, Derynck R (2001). TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol, 11, 44-51.
2. Bierie B, Moses HL (2006). Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer, 6, 506-20.
3. Buck MB, Fritz P, Dippon J, et al (2004). Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res, 10, 491-8.
4. Centuori SM, Trad M, LaCasse CJ, et al (2012). Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-beta-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3-T cells. J Leukoc Biol, 92, 987-97.
5. Chen W, Jin W, Hardegen N, et al (2003). Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 198, 1875-86.
6. Chung DJ, Rossi M, Romano E, et al (2009). Indoleamine 2, 3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood, 114, 555-63.
7. Curiel TJ, Coukos G, Zou L, et al (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 10, 942-9.
8. Donkor MK, Sarkar A, Li MO (2012). Tgf-beta1 produced by activated CD4 (+) T cells antagonizes T cell surveillance of tumor development. Oncoimmunology, 1, 162-71.
9. Ghiringhelli F, Puig PE, Roux S, et al (2005). Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med, 202, 919-29.
10. Gorelik L, Flavell RA (2001). Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med, 7, 1118-22.
11. Hu JL, Yang Z, Tang JR, et al (2013). Effects of gastric cancer cells on the differentiation of Treg cells. Asian Pac J Cancer Prev, 14, 4607-10.
12. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ (2000). Early detection and treatment of skin cancer. Am Fam Physician, 62, 357-68, 75-6, 81-2.
13. Kulkarni AB, Huh CG, Becker D, et al (1993). Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A, 90, 770-4.
14. Li MO, Flavell RA (2008). TGF-beta: a master of all T cell trades. Cell, 134, 392-404.
15. Li Z, Chen L, Rubinstein MP (2013). Cancer immunotherapy: are we there yet? Exp Hematol Oncol, 2, 33.
16. Liu CY, Wang YM, Wang CL, et al (2010). Population alterations of L-arginase-and inducible nitric oxide synthase-expressed CD11b+/CD14 (-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol, 136, 35-45.
17. Marigo I, Dolcetti L, Serafini P, et al (2008). Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev, 222, 162-79.
18. Massague J (2008). TGFbeta in Cancer. Cell, 134, 215-30.
19. McKarns SC, Schwartz RH, Kaminski NE (2004). Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol, 172, 4275-84.
20. Siegel PM, Massague J (2003). Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer, 3, 807-21.
21. Thomas DA, Massague J (2005). TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell, 8, 369-80.
22. Tripsianis G, Papadopoulou E, Romanidis K (2013). Overall survival and clinicopathological characteristics of patients with breast cancer in relation to the expression pattern of HER-2, IL-6, TNF-alpha and TGF-beta1. Asian Pac J Cancer Prev, 14, 6813-20.
23. Willimsky G, Blankenstein T (2005). Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature, 437, 141-6.
24. Yamazaki S, Iyoda T, Tarbell K, et al (2003). Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med, 198, 235-47.
25. Yang L, Huang J, Ren X, et al (2008). Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell, 13, 23-35.
26. Zou W (2006). Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol, 6, 295-307.